Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

The Horizon: Gene Therapy and Future Research

At a Glance

The future of Limb-Girdle Muscular Dystrophy (LGMD) treatment involves AAV gene therapies that aim to fix the disease's root genetic cause. Having a confirmed genetic subtype diagnosis is essential, as these experimental treatments target specific gene mutations.

The landscape of Limb-Girdle Muscular Dystrophy (LGMD) is shifting from “managing symptoms” to “fixing the root cause.” While there is not yet a cure, we are entering an era of precision medicine where treatments are being designed specifically for your unique genetic code [1][2].

The Promise of Gene Therapy

The most significant area of research is AAV gene therapy. This technology uses a harmless, modified virus called an adeno-associated virus (AAV) to deliver a healthy, working copy of a gene directly into your muscle cells [2][3].

  • LGMDR4 (Beta-Sarcoglycanopathy): One of the furthest-along therapies is bidridistrogene xeboparvovec (also known as SRP-9003). In Phase 1/2 clinical trials, this therapy has shown a safe profile and significantly increased the production of the missing beta-sarcoglycan protein in patients’ muscles over a two-year period [2][4].
  • LGMDR9 (FKRP-related): Trials for LGMDR9 (such as the study of AB-1003) are currently underway to evaluate safety and how well the new gene is tolerated in adults [NCT05230459].
  • LGMDR1 (Calpainopathy): Preclinical studies—the research done before human trials—have shown that LGMDR1 is a “highly suitable” candidate for gene replacement, with early tests showing improved muscle physiology [5][6].

Overcoming Scientific Hurdles

Developing these treatments is complex, and researchers are working to solve several key challenges:

  • AAV Immunity: Many people have pre-existing neutralizing antibodies against AAV because it is a virus found in nature. If you have these antibodies, your immune system might “attack” the therapy before it can work [7][8].
  • The “One-Shot” Limitation: Currently, gene therapy is a one-time treatment. Because the body develops antibodies after the first dose, it is difficult to “re-dose” if the effect wears off [7][9].
  • Packaging Space: Some LGMD genes are too large to fit inside a standard AAV “delivery truck.” Scientists are developing “split-gene” strategies to carry the code in two separate pieces that stitch themselves together inside the muscle cell [10][11].

The Power of Your Data

You don’t have to wait for a drug trial to contribute to a cure. Natural history studies and patient registries are the backbone of modern research.

Why Natural History Matters

Studies like JOURNEY LGMD or the GRASP-LGMD consortium track how LGMD progresses over several years without any new drugs [12][13].

  • The Standard of Comparison: Because LGMD is rare, there are often not enough patients to have a “placebo group” in a trial. Regulators (like the FDA) use natural history data as the “benchmark” to see if a new drug is actually working [13][14].
  • Validated Tools: These studies help refine tools like the North Star Assessment (NSAD), a series of movements that measure muscle function accurately in a clinical setting [15][16].

The Importance of Genetic Confirmation

None of these future treatments are “one size fits all.” Eligibility for nearly every gene therapy trial requires a definitive genetic diagnosis [1][NCT05230459]. If you only have a clinical diagnosis (based on symptoms alone), confirming your specific “D” or “R” subtype is the most important step you can take today to prepare for the treatments of tomorrow.

Common questions in this guide

What is AAV gene therapy for LGMD?
AAV gene therapy uses a harmless, modified virus to deliver a healthy, working copy of a missing or defective gene directly into your muscle cells. It aims to treat the root cause of certain limb-girdle muscular dystrophy subtypes.
Why do I need a genetic test to participate in LGMD clinical trials?
Future treatments like gene therapy are not one-size-fits-all. A definitive genetic diagnosis confirming your specific LGMD subtype is required for clinical trial eligibility because each therapy targets a specific genetic mutation.
What are natural history studies for LGMD?
Natural history studies track how the disease progresses over time without any new drugs. Since LGMD is rare, researchers and regulators use this data as a benchmark to see if an experimental new drug is actually working.
Can pre-existing immunity affect gene therapy?
Yes, many people naturally have antibodies against the viruses used in gene therapy delivery. If you have these neutralizing antibodies, your immune system might attack the therapy before it can effectively treat your muscles, which may impact your eligibility for trials.
Why is gene therapy currently considered a one-time treatment?
After receiving the first dose of gene therapy, your body develops antibodies against the viral vector used to deliver it. This immune response makes it very difficult to administer a second dose safely and effectively if the initial treatment wears off.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my specific genetic subtype (e.g., LGMDR4, LGMDR9) currently being studied in active gene therapy clinical trials?
  2. 2.Should I be tested for pre-existing AAV antibodies to see if I might be eligible for future gene therapy?
  3. 3.Can you help me find and enroll in a natural history study like JOURNEY LGMD or a registry like CMDIR?
  4. 4.How do these experimental therapies differ from the supportive care I am currently receiving?
  5. 5.What are the potential side effects or immune risks associated with AAV gene therapy that we should be aware of?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Genetically confirmed limb-girdle muscular dystrophy type 2B with DYSF mutation using gene panel sequencing: A case report.

    Lee SJ, Choi E, Shin S, Park J

    Medicine 2020; (99(28)):e20810 doi:10.1097/MD.0000000000020810.

    PMID: 32664072
  2. 2

    Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results.

    Mendell JR, Pozsgai ER, Lewis S, et al.

    Nature medicine 2024; (30(1)):199-206 doi:10.1038/s41591-023-02730-9.

    PMID: 38177855
  3. 3

    AAV-based TCAP delivery rescues mitochondria dislocation in limb-girdle muscular dystrophy R7.

    Lv X, Liu S, Li X, et al.

    Brain : a journal of neurology 2025; (148(5)):1680-1694 doi:10.1093/brain/awae351.

    PMID: 39468783
  4. 4

    Pharmacokinetic and Pharmacodynamic Evaluation of Bidridistrogene Xeboparvovec in an Aged Murine Model of Limb-Girdle Muscular Dystrophy Type 2E/R4.

    Baine S, Cui J, Seo YE, et al.

    Human gene therapy 2026; (37(3-4)):93-101 doi:10.1177/10430342251393700.

    PMID: 41194675
  5. 5

    Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1.

    Sahenk Z, Ozes B, Murrey D, et al.

    Molecular therapy. Methods & clinical development 2021; (22()):401-414 doi:10.1016/j.omtm.2021.06.010.

    PMID: 34514031
  6. 6

    [Calpainopathies: state of the art and therapeutic perspectives].

    Malfatti E, Richard I

    Medecine sciences : M/S 2020; (36 Hors série n° 2()):17-21 doi:10.1051/medsci/2020244.

    PMID: 33427631
  7. 7

    Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors.

    Gardin A, Ronzitti G

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2023; (30(8S1)):8S46-8S52 doi:10.1016/S0929-693X(23)00227-0.

    PMID: 38043983
  8. 8

    Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies.

    Duan D, Herzog RW

    Molecular therapy : the journal of the American Society of Gene Therapy 2026; (34(4)):1893-1908 doi:10.1016/j.ymthe.2025.12.067.

    PMID: 41502088
  9. 9

    Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions.

    Weber T

    Frontiers in immunology 2021; (12()):658399 doi:10.3389/fimmu.2021.658399.

    PMID: 33815421
  10. 10

    Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system.

    Datta P, Rhee KD, Staudt RJ, et al.

    Human molecular genetics 2024; (33(24)):2094-2110 doi:10.1093/hmg/ddae144.

    PMID: 39393808
  11. 11

    Split intein-mediated protein trans-splicing to express large dystrophins.

    Tasfaout H, Halbert CL, McMillen TS, et al.

    Nature 2024; (632(8023)):192-200 doi:10.1038/s41586-024-07710-8.

    PMID: 39020181
  12. 12

    Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study.

    Doody A, Alfano L, Diaz-Manera J, et al.

    BMC neurology 2024; (24(1)):96 doi:10.1186/s12883-024-03588-1.

    PMID: 38491364
  13. 13

    Limb-Girdle Muscular Dystrophy Scientific Workshop: A Multistakeholder Discussion Focused on Charting the Path Forward for Drug Development.

    Wicklund MP, Alfano LN, Johnson NE, et al.

    Neurology. Clinical practice 2025; (15(5)):e200496 doi:10.1212/CPJ.0000000000200496.

    PMID: 40756520
  14. 14

    Limb Girdle Muscular Dystrophies.

    Bockhorst J, Wicklund M

    Neurologic clinics 2020; (38(3)):493-504 doi:10.1016/j.ncl.2020.03.009.

    PMID: 32703463
  15. 15

    Validation of the North Star Assessment for Limb-Girdle Type Muscular Dystrophies.

    James MK, Alfano LN, Muni-Lofra R, et al.

    Physical therapy 2022; (102(10)) doi:10.1093/ptj/pzac113.

    PMID: 35932452
  16. 16

    Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale.

    Jacobs MB, James MK, Lowes LP, et al.

    Annals of neurology 2021; (89(5)):967-978 doi:10.1002/ana.26044.

    PMID: 33576057

This page provides information about experimental LGMD gene therapies and research for educational purposes only. Always consult your neurologist or geneticist regarding your diagnosis and clinical trial eligibility.

Get notified when new evidence is published on Limb-girdle muscular dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.